These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 31288034)

  • 21. Chromatographic behavior of bivalent bispecific antibodies on cation exchange columns. II. Biomolecular perspectives.
    Kimerer LK; Pabst TM; Hunter AK; Carta G
    J Chromatogr A; 2019 Sep; 1601():133-144. PubMed ID: 31054833
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A new model for intermediate molecular weight recombinant bispecific and trispecific antibodies by efficient heterodimerization of single chain variable domains through fusion to a Fab-chain.
    Schoonjans R; Willems A; Schoonooghe S; Leoen J; Grooten J; Mertens N
    Biomol Eng; 2001 Jun; 17(6):193-202. PubMed ID: 11337278
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A single mutation increases heavy-chain heterodimer assembly of bispecific antibodies by inducing structural disorder in one homodimer species.
    Stutz C; Blein S
    J Biol Chem; 2020 Jul; 295(28):9392-9408. PubMed ID: 32404368
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single-domain antibody-based and linker-free bispecific antibodies targeting FcγRIII induce potent antitumor activity without recruiting regulatory T cells.
    Rozan C; Cornillon A; Pétiard C; Chartier M; Behar G; Boix C; Kerfelec B; Robert B; Pèlegrin A; Chames P; Teillaud JL; Baty D
    Mol Cancer Ther; 2013 Aug; 12(8):1481-91. PubMed ID: 23757164
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlations between changes in conformational dynamics and physical stability in a mutant IgG1 mAb engineered for extended serum half-life.
    Majumdar R; Esfandiary R; Bishop SM; Samra HS; Middaugh CR; Volkin DB; Weis DD
    MAbs; 2015; 7(1):84-95. PubMed ID: 25524268
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Highly effective recombinant format of a humanized IgG-like bispecific antibody for cancer immunotherapy with retargeting of lymphocytes to tumor cells.
    Asano R; Watanabe Y; Kawaguchi H; Fukazawa H; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
    J Biol Chem; 2007 Sep; 282(38):27659-65. PubMed ID: 17644522
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structural and Functional Characterization of a Hole-Hole Homodimer Variant in a "Knob-Into-Hole" Bispecific Antibody.
    Zhang HM; Li C; Lei M; Lundin V; Lee HY; Ninonuevo M; Lin K; Han G; Sandoval W; Lei D; Ren G; Zhang J; Liu H
    Anal Chem; 2017 Dec; 89(24):13494-13501. PubMed ID: 29129068
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparison of biophysical characterization techniques in predicting monoclonal antibody stability.
    Thiagarajan G; Semple A; James JK; Cheung JK; Shameem M
    MAbs; 2016; 8(6):1088-97. PubMed ID: 27210456
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Understanding the Increased Aggregation Propensity of a Light-Exposed IgG1 Monoclonal Antibody Using Hydrogen Exchange Mass Spectrometry, Biophysical Characterization, and Structural Analysis.
    Bommana R; Chai Q; Schöneich C; Weiss WF; Majumdar R
    J Pharm Sci; 2018 Jun; 107(6):1498-1511. PubMed ID: 29408480
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
    Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
    MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relative Contribution of Framework and CDR Regions in Antibody Variable Domains to Multimerisation of Fv- and scFv-Containing Bispecific Antibodies.
    Bhatta P; Humphreys DP
    Antibodies (Basel); 2018 Aug; 7(3):. PubMed ID: 31544885
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nanocell targeting using engineered bispecific antibodies.
    Taylor K; Howard CB; Jones ML; Sedliarou I; MacDiarmid J; Brahmbhatt H; Munro TP; Mahler SM
    MAbs; 2015; 7(1):53-65. PubMed ID: 25523746
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Engineering of stable bispecific antibodies targeting IL-17A and IL-23.
    Mabry R; Lewis KE; Moore M; McKernan PA; Bukowski TR; Bontadelli K; Brender T; Okada S; Lum K; West J; Kuijper JL; Ardourel D; Franke S; Lockwood L; Vu T; Frank A; Appleby MW; Wolf A; Reardon B; Hamacher NB; Stevens B; Lewis P; Lewis KB; Gilbertson DG; Lantry M; Julien SH; Ostrander C; Chan C; Byrnes-Blake K; Brody J; Presnell S; Meengs B; Levin SD; Snavely M
    Protein Eng Des Sel; 2010 Mar; 23(3):115-27. PubMed ID: 20022918
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies.
    Muda M; Gross AW; Dawson JP; He C; Kurosawa E; Schweickhardt R; Dugas M; Soloviev M; Bernhardt A; Fischer D; Wesolowski JS; Kelton C; Neuteboom B; Hock B
    Protein Eng Des Sel; 2011 May; 24(5):447-54. PubMed ID: 21498564
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Engineering the hinge region of human IgG1 Fc-fused bispecific antibodies to improve fragmentation resistance.
    Suzuki S; Annaka H; Konno S; Kumagai I; Asano R
    Sci Rep; 2018 Nov; 8(1):17253. PubMed ID: 30467410
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sheathless CE-MS as a tool for monitoring exchange efficiency and stability of bispecific antibodies.
    Gstöttner C; Vergoossen DLE; Wuhrer M; Huijbers MGM; Domínguez-Vega E
    Electrophoresis; 2021 Jan; 42(1-2):171-176. PubMed ID: 32901958
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Shortened Hinge Design of Fab x sdAb-Fc Bispecific Antibodies Enhances Redirected T-Cell Killing of Tumor Cells.
    Huang S; Segués A; Waterfall M; Wright D; Vayssiere C; van Duijnhoven SMJ; van Elsas A; Sijts AJAM; Zaiss DM
    Biomolecules; 2022 Sep; 12(10):. PubMed ID: 36291540
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells.
    Satta A; Mezzanzanica D; Caroli F; Frigerio B; Di Nicola M; Kontermann RE; Iacovelli F; Desideri A; Anichini A; Canevari S; Gianni AM; Figini M
    MAbs; 2018 Oct; 10(7):1084-1097. PubMed ID: 29993310
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Insertion of scFv into the hinge domain of full-length IgG1 monoclonal antibody results in tetravalent bispecific molecule with robust properties.
    Bezabeh B; Fleming R; Fazenbaker C; Zhong H; Coffman K; Yu XQ; Leow CC; Gibson N; Wilson S; Stover CK; Wu H; Gao C; Dimasi N
    MAbs; 2017; 9(2):240-256. PubMed ID: 27981887
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cysteine-SILAC Mass Spectrometry Enabling the Identification and Quantitation of Scrambled Interchain Disulfide Bonds: Preservation of Native Heavy-Light Chain Pairing in Bispecific IgGs Generated by Controlled Fab-arm Exchange.
    van den Bremer ETJ; Labrijn AF; van den Boogaard R; Priem P; Scheffler K; Melis JPM; Schuurman J; Parren PWHI; de Jong RN
    Anal Chem; 2017 Oct; 89(20):10873-10882. PubMed ID: 28922593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.